Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

1.310 -0.050 (-3.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Provides Half Year 2024 Corporate Update
Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Reports Results of 2024 Annual General Meeting
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Reports Full Year 2023 Financial Results
ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare System 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
Company opens own physician-led laboratory, ‘European Oncology Lab’ (EOL), thereby offering ColoAlert® as a laboratory medical service directly to physicians and patients 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Provides Year-End Corporate Review 2023
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and... 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
From Mainz BioMed NV
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.